Literature DB >> 21886642

Successful treatment of uncomplicated gonococcal urethritis in HIV-infected patients with single-dose oral cefpodoxime.

George Psevdos1, Victoria Sharp.   

Abstract

Fluoroquinolones are no longer recommended for the treatment of gonococcal infections in the United States. Cephalosporins - ceftriaxone and cefixime - are the treatment of choice, as suggested by the Centers for Disease Control and Prevention (USA). There are limited data on the efficacy of cefpodoxime for the treatment of uncomplicated gonococcal infections. Two cases of HIV-infected homosexual men who were successfully treated with cefpodoxime for urethritis caused by Neisseria gonorrhoeae are described in the present study.

Entities:  

Keywords:  Cefpodoxime; HIV/AIDS; Neisseria gonorrhoeae

Year:  2010        PMID: 21886642      PMCID: PMC2951812          DOI: 10.1155/2010/561908

Source DB:  PubMed          Journal:  Can J Infect Dis Med Microbiol        ISSN: 1712-9532            Impact factor:   2.471


  5 in total

Review 1.  Emerging antimicrobial resistance in Neisseria gonorrhoeae: urgent need to strengthen prevention strategies.

Authors:  Kimberly A Workowski; Stuart M Berman; John M Douglas
Journal:  Ann Intern Med       Date:  2008-04-15       Impact factor: 25.391

2.  Update to CDC's sexually transmitted diseases treatment guidelines, 2006: fluoroquinolones no longer recommended for treatment of gonococcal infections.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2007-04-13       Impact factor: 17.586

Review 3.  Neisseria gonorrhoeae and emerging resistance to extended spectrum cephalosporins.

Authors:  John W Tapsall
Journal:  Curr Opin Infect Dis       Date:  2009-02       Impact factor: 4.915

Review 4.  Drugs of choice for the treatment of uncomplicated gonococcal infections.

Authors:  J S Moran; W C Levine
Journal:  Clin Infect Dis       Date:  1995-04       Impact factor: 9.079

5.  Orally administered cefpodoxime proxetil for treatment of uncomplicated gonococcal urethritis in males: a dose-response study.

Authors:  E Novak; L M Paxton; H J Tubbs; L F Turner; C W Keck; J Yatsu
Journal:  Antimicrob Agents Chemother       Date:  1992-08       Impact factor: 5.191

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.